Lumos Pharma, Inc.
NASDAQ:LUMO
Overview | Financials
Company Name | Lumos Pharma, Inc. |
Symbol | LUMO |
Currency | USD |
Price | 4.34 |
Market Cap | 37,535,011 |
Dividend Yield | 0% |
52-week-range | 1.37 - 4.576 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Richard J. Hawkins |
Website | https://www.lumos-pharma.com |
An error occurred while fetching data.
About Lumos Pharma, Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD